Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Takeda’s RCC Drug Cabometyx in MHLW Panel’s Review Roster for January 29; Alecensa, Opdivo and More
January 16, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
- Australia to Provide Expedited Reviews for OTC and Quasi-Drugs Approved in Japan
January 16, 2020
- Rotavirus Vaccine to Be Included in Public Vaccination Programs Starting Oct. 1
January 16, 2020
- Novartis’ Eylea Contender Up for MHLW Panel Review on January 27
January 15, 2020
- Japan Approves 2 HIV Drugs, Listing Expected Soon
January 15, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
- MHLW to Beef Up GMP Inspections at API Manufacturing Sites in Asia from FY2020 in Response to Series of Supply Disruptions
January 6, 2020
- MHLW Revises Safety Guidance on FIH Studies Following Death of Subject
January 6, 2020
- MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
- JETRO’s New York Office Gets First Health and Welfare Head in 2 Years
January 1, 2020
- Councilor Mori Urges Drug Maker Management to Straighten Up as He Bids Farewell to MHLW
December 27, 2019
- Health Ministry Panel Calls for Simplified Certification Process for Vaccines to Ensure Stable Supplies
December 27, 2019
- Japan Lays Out Action Plan for Whole Genome Analysis; Preliminary Project to Cover 64,000 Cancer Patients, 28,000 for Intractable Diseases
December 27, 2019
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
- MHLW to Establish Clinical Research Centers for Pediatric, Rare Diseases: FY2020 Budget
December 25, 2019
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…